Globus Medical, Inc. $GMED Holdings Increased by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 51.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,510 shares of the medical device company’s stock after buying an additional 12,000 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Globus Medical were worth $2,660,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Janus Henderson Group PLC grew its position in shares of Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after purchasing an additional 328,217 shares in the last quarter. Sculptor Capital LP lifted its position in Globus Medical by 1.9% during the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock worth $263,477,000 after buying an additional 58,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Globus Medical by 2.0% during the first quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after buying an additional 33,976 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Globus Medical by 2.8% during the first quarter. The Manufacturers Life Insurance Company now owns 1,132,278 shares of the medical device company’s stock worth $97,557,000 after buying an additional 30,412 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Globus Medical by 107.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock worth $78,656,000 after buying an additional 471,875 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Insider Activity

In related news, Director Stephen Zarrilli sold 25,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares in the company, valued at $2,176,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James R. Tobin sold 30,000 shares of Globus Medical stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the director directly owned 15,000 shares of the company’s stock, valued at $1,118,700. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 18.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on GMED shares. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. UBS Group began coverage on shares of Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 target price on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research note on Friday, September 18th. Finally, Royal Bank Of Canada cut their price target on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, October 1st. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.46.

Globus Medical Stock Performance

Shares of Globus Medical stock opened at $79.53 on Tuesday. The company has a market capitalization of $10.68 billion, a P/E ratio of 20.34, a PEG ratio of 1.31 and a beta of 0.96. Globus Medical, Inc. has a 1 year low of $59.51 and a 1 year high of $101.40. The company’s fifty day moving average is $77.49 and its two-hundred day moving average is $83.45.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.24. The firm had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, equities analysts expect that Globus Medical, Inc. will post 4.99 earnings per share for the current year.

Globus Medical Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.